VNDA · NASDAQ
Vanda Pharmaceuticals Inc.
$4.18 +0.19 (+4.76%)
Company overview
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies to address high unmet medical needs. Its marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders and Fanapt oral tablets for schizophrenia. The company's pipeline includes HETLIOZ (tasimelteon) being developed for jet lag disorder, Smith-Magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for bipolar disorder and a long-acting injectable formulation for schizophrenia; and Tradipitant (VLY-686), a neurokinin-1 receptor antagonist for treating atopic dermatitis, gastroparesis, and motion sickness.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $253M
- Employees
- 368
- Headquarters
- Washington, DC
- Website
- vandapharma.com
- CEO
- Mihael H. Polymeropoulos
- Listed
- April 12, 2006
- P/E
- -1.03
- Dividend yield
- 0.00%
Company financials
- Revenue
- $218M
- Gross profit
- $201M
- Operating income
- -$160M
- EBITDA
- -$143M
- Net income
- -$240M
- EPS
- -$4.05
- Total assets
- $434M
- Total debt
- $13.1M
- Gross margin
- 92.46%
- Net margin
- -109.99%
- Earnings yield
- -96.89%
No geographic segmentation.
Showing FY 2025
VNDA
1D
NASDAQ
O4.04H4.11L3.88C3.99+0.05 (+1.27%)Vol1.86M